Efforts to develop drugs to combat sarcopenia are currently underway, with companies exploring new strategies to tackle age-related muscle loss. While resistance exercise remains an effective method, drug developers are now looking into the use of antidiabetic GLP1 receptor agonists for weight loss, which may have the side effect of minimizing muscle loss. However, concerns remain about the focus shifting away from age-related diseases to more trendy health issues. Companies like BioAge Labs, Regeneron, and others are combining their muscle-building drugs with GLP-1 agonists to preserve lean muscle mass and enhance weight loss. Immunis and Juvena Therapeutics are looking into muscle stem cell secretome, while Biophytis focuses on shared pathways between sarcopenia and neuromuscular diseases. This shift in focus towards preserving muscle mass in obesity studies highlights the importance of finding innovative solutions to combat muscle atrophy. For more information, you can visit the link: https://doi.org/10.1038/s41587-024-02176-5